Shaily Engineering Plastics Ltd. Q2 FY27 Investor Presentation Released
Shaily Engineering Plastics released its Q2 FY27 investor presentation. Revenues grew 24% YoY to ₹319.5 Crs, and PAT rose 20% to ₹61.3 Crs. H1 FY27 revenues increased 19% to ₹600.2 Crs. Key developments include launching a reusable auto-injector pen and investing ₹350 Crs in an Abu Dhabi facility for medical devices. Short-term bank facilities were upgraded to CARE A1+.
The announcement includes significant financial growth, strategic investments in new facilities and product lines (especially in the high-growth healthcare sector), and a credit rating upgrade, all of which are material to investors.
The company reported strong year-on-year growth in revenue and profit, alongside positive business developments such as new product launches, capacity expansions, and a credit rating upgrade. The new healthcare product and Abu Dhabi facility investment indicate strategic growth initiatives.
Shaily Engineering Plastics Limited (SEPL) has released its Investor Presentation for the second quarter and first half of fiscal year 2027, covering the period ended September 30, 2026. This follows the company's earnings call scheduled for October 30, 2026, at 4:00 p.m. IST.
The presentation highlights key business updates, including new product confirmations for both the consumer and industrial segments. In the consumer division, new product and increased volume orders were received from a home furnishing customer. For the industrial segment, SEPL secured business confirmations for seven new products in power tools and new knobs from an appliance customer.
A significant development is the rating upgrade for Shaily Engineering Plastics Limited's short-term bank facilities from CARE A1 to CARE A1+ by CARE Ratings, covering ₹35 Crs.
The company is also expanding its healthcare offerings with two new contracts for IP-led platforms and the launch of a two-step reusable auto-injector pen for GLP-1 therapies, named Shaily AI TobyTM Reusable. This innovative product aims for sustainability by using less material and lower energy consumption compared to fully disposable auto-injectors. Capacity additions are underway, with 25 million pens expected to be added through automation machines currently under commissioning. Furthermore, SEPL is establishing a facility in Abu Dhabi for manufacturing medical devices, with an expected investment of AED 130-150 million (approximately ₹350 Crs), projected to add a capacity of 75 million pens annually.
Financially, for Q2 FY27, Shaily Engineering Plastics reported consolidated revenues of ₹319.5 Crs, a 24% increase year-on-year, and Profit After Tax (PAT) of ₹61.3 Crs, up 20%. For H1 FY27, revenues grew 19% to ₹600.2 Crs, with PAT increasing by 18% to ₹109.3 Crs. The company noted improved traction in the healthcare segment as a key driver for overall business growth, despite weaker market demand for home furnishings in Europe and the USA. Machine utilization across plants improved to 52.5% in Q2 FY27 from 47.8% in Q2 FY26. The company's Return on Capital Employed (RoCE) improved to 29.7% in Sep-26 from 26.9% in Mar-26.
What to do with a filing like this
Shaily Engineering Plastics Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shaily Engineering Plastics Limited. Read the original for the full detail.